Document Detail


Observer variation in FDG PET-CT for staging of non-small-cell lung carcinoma.
MedLine Citation:
PMID:  18828012     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: Error and variation in reporting remains one of the weakest features of clinical imaging despite enormous technological advances in nuclear medicine and radiology. The aim of this study was to evaluate agreement amongst experienced readers in staging non-small-cell lung cancer (NSCLC) with PET-CT. METHODS: A series of (18)F-FDG PET-CT scans from 100 consecutive patients were reviewed independently by three experienced readers, with two readers reviewing each scan series a second time. Individual mediastinal lymph node stations were assessed as benign/inflammatory, equivocal or malignant, and AJCC N and M stage were also assigned. Kappa (kappa) was used to compare ratings from two categories and weighted kappa (kappa(w)) for three or more categories, and kappa values were interpreted according to the Landis-Koch benchmarks. RESULTS: Both intra- and interobserver agreement for N and M staging were high. For M staging there was almost perfect intra- and interobserver agreement (kappa = 0.90-0.93). For N staging, agreement was either almost perfect or substantial (intraobserver kappa(w) = 0.79, 0.91; interobserver kappa(w) = 0.75-0.81). Importantly, there was almost perfect agreement for N0/1 vs N2/3 disease (kappa = 0.80-0.97). Agreement for inferior and superior mediastinal nodes (stations 1, 2, 3, 7, 8, 9) was either almost perfect or substantial (kappa(w) = 0.71-0.88), but lower for hilar nodes (10; kappa(w) = 0.56-0.71). Interreporter variability was greatest for aortopulmonary nodes (5, 6; kappa(w) = 0.48-0.55). CONCLUSION: Amongst experienced reporters in a single centre, there was a very high level of agreement for both mediastinal nodal stage and detection of distant metastases with PET-CT. This supports the use of PET-CT as a robust imaging modality for staging NSCLC.
Authors:
Michael S Hofman; Nigel C Smeeton; Sheila C Rankin; Tom Nunan; Michael J O'Doherty
Publication Detail:
Type:  Journal Article     Date:  2008-10-01
Journal Detail:
Title:  European journal of nuclear medicine and molecular imaging     Volume:  36     ISSN:  1619-7089     ISO Abbreviation:  Eur. J. Nucl. Med. Mol. Imaging     Publication Date:  2009 Feb 
Date Detail:
Created Date:  2009-01-27     Completed Date:  2009-03-18     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101140988     Medline TA:  Eur J Nucl Med Mol Imaging     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  194-9     Citation Subset:  IM    
Affiliation:
PET Imaging Centre, St Thomas' Hospital, Lambeth Palace Road, London, SE1 7EH, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Carcinoma, Non-Small-Cell Lung / diagnosis*,  pathology*,  radiography,  radionuclide imaging
Fluorodeoxyglucose F18 / diagnostic use*
Humans
Neoplasm Metastasis
Neoplasm Staging / methods*
Observer Variation
Positron-Emission Tomography / statistics & numerical data*
Referral and Consultation
Tomography, X-Ray Computed / statistics & numerical data*
Chemical
Reg. No./Substance:
63503-12-8/Fluorodeoxyglucose F18

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Combined CT and fluoroscopic guidance of balloon kyphoplasty versus fluoroscopy-only procedures.
Next Document:  Longitudinal assessment of cerebral 5-HT2A receptors in healthy elderly volunteers: an [18F]-altanse...